Company intelligence / Profile preview

TOA EIYO

Chuo-ku, Tokyo, Japantoaeiyo.co.jp ↗
Ownership
Private
Development stage
Other
01

Overview

TOA EIYO has several approved drugs in Japan, primarily for cardiovascular diseases, gout, and vitamin deficiencies. Notable products include long-standing treatments for angina pectoris and myocardial ischemia such as Frandol® and Bisono® tape.

Therapeutic areas
Metabolic DisordersOncologyRheumatologyCardiovascular
Modalities
Small moleculeBiologic
Industry
Biotech
02

Drug pipeline

3 assets

bisoprolol (TOA EIYO)

Unknown

2 more assets in the full pipeline.

Request access →
03

Partnerships

Astellas Pharma Inc.

Beyond the preview

Go deeper on TOA EIYO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOA EIYO.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call